In fact, numerous preliminary clinical studies have demonstrated that venetoclax, an oral potent BCL2 antagonist approved to treat multiple hematological malignancies, plus standard-of-care regimens yield a survival benefit for BCL2-overexpressed DLBCL patients (17). The gene discussed is BCL2; the disease is hematologic disorder.